JP5721275B2 - 治療的使用のための新規７−デアザプリンヌクレオシド - Google Patents

治療的使用のための新規７−デアザプリンヌクレオシド Download PDF

Info

Publication number
JP5721275B2
JP5721275B2 JP2012506333A JP2012506333A JP5721275B2 JP 5721275 B2 JP5721275 B2 JP 5721275B2 JP 2012506333 A JP2012506333 A JP 2012506333A JP 2012506333 A JP2012506333 A JP 2012506333A JP 5721275 B2 JP5721275 B2 JP 5721275B2
Authority
JP
Japan
Prior art keywords
compound
compound according
ddd
nmr
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012506333A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012524731A (ja
JP2012524731A5 (enExample
Inventor
アウレリー ボーデルー，
アウレリー ボーデルー，
マイケル ホセク，
マイケル ホセク，
ペトル ナウス，
ペトル ナウス，
Original Assignee
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．, インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． filed Critical インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ．
Publication of JP2012524731A publication Critical patent/JP2012524731A/ja
Publication of JP2012524731A5 publication Critical patent/JP2012524731A5/ja
Application granted granted Critical
Publication of JP5721275B2 publication Critical patent/JP5721275B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2012506333A 2009-04-22 2010-04-19 治療的使用のための新規７−デアザプリンヌクレオシド Active JP5721275B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17165609P 2009-04-22 2009-04-22
US61/171,656 2009-04-22
PCT/CZ2010/000050 WO2010121576A2 (en) 2009-04-22 2010-04-19 Novel 7-deazapurine nucleosides for therapeutic uses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014213410A Division JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Publications (3)

Publication Number Publication Date
JP2012524731A JP2012524731A (ja) 2012-10-18
JP2012524731A5 JP2012524731A5 (enExample) 2013-05-30
JP5721275B2 true JP5721275B2 (ja) 2015-05-20

Family

ID=42768153

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012506333A Active JP5721275B2 (ja) 2009-04-22 2010-04-19 治療的使用のための新規７−デアザプリンヌクレオシド
JP2014213410A Active JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014213410A Active JP6087889B2 (ja) 2009-04-22 2014-10-20 治療的使用のための新規７−デアザプリンヌクレオシド

Country Status (15)

Country Link
US (3) US9321800B2 (enExample)
EP (1) EP2421879B1 (enExample)
JP (2) JP5721275B2 (enExample)
CN (2) CN104497084B (enExample)
AU (3) AU2010238985B2 (enExample)
CA (2) CA2759131C (enExample)
DK (1) DK2421879T3 (enExample)
ES (1) ES2437917T3 (enExample)
HR (1) HRP20131021T1 (enExample)
MX (1) MX2011011160A (enExample)
NZ (2) NZ596301A (enExample)
PL (1) PL2421879T3 (enExample)
PT (1) PT2421879E (enExample)
SI (1) SI2421879T1 (enExample)
WO (1) WO2010121576A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド
EA201270661A1 (ru) * 2009-12-18 2013-06-28 Президент Энд Феллоуз Оф Гарвард Колледж УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN102319254B (zh) * 2011-07-20 2013-06-19 上海交通大学 5-碘代杀菌核素在制备抗肿瘤药物中的应用
CZ305466B6 (cs) * 2013-11-04 2015-10-14 Ústav organické chemie a biochemie Akademie věd České republiky, v. v. i. Substituované 7-deazapurinové ribonukleosidy pro terapeutické použití
CA2967125C (en) 2014-11-14 2022-10-25 Nerviano Medical Sciences S.R.L. 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
US10414788B2 (en) 2016-06-29 2019-09-17 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
CA3049136C (en) 2017-01-18 2022-06-14 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
CN118440096A (zh) 2017-06-20 2024-08-06 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
US11072628B2 (en) 2017-10-19 2021-07-27 Universiteit Gent Nucleoside analogues for the treatment of parasitic infections
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
CA3087354C (en) * 2018-01-18 2023-01-03 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
WO2019143994A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrazolyl[4,3-c]pyridinecompounds as ret kinase inhibitors
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
EP3833355A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
CN112996794A (zh) 2018-09-10 2021-06-18 阿雷生物药品公司 作为ret激酶抑制剂的稠合杂环化合物
MX2021015772A (es) * 2019-06-18 2022-01-31 Taiho Pharmaceutical Co Ltd Compuesto de carbonato novedoso que tiene esqueleto de pirrolopirimidina o sal farmaceuticamente aceptable del mismo.
US20230104311A1 (en) * 2020-02-17 2023-04-06 Katholieke Universiteit Leuven Novel 6-substituted 7-deazapurines and corresponding nucleosides as medicaments
KR102639275B1 (ko) * 2021-06-08 2024-02-21 퓨쳐메디신 주식회사 다중 표적 인산화효소 저해 활성을 갖는 뉴클레오사이드 유도체 및 이를 포함하는 암의 예방 및 치료용 약학적 조성물
CA3233416A1 (en) 2021-09-28 2023-04-06 Universiteit Antwerpen Nucleoside analogues for the treatment of parasitic infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108523A0 (en) * 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
HUP0400726A3 (en) * 2001-01-22 2007-05-29 Merck & Co Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2002353165A1 (en) * 2001-12-17 2003-06-30 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
AU2003232071A1 (en) * 2002-05-06 2003-11-17 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection
US20040157892A1 (en) 2003-02-12 2004-08-12 Crompton Co./Cie Pesticidal fluoroethyl pyrazoles
US7157434B2 (en) * 2003-10-27 2007-01-02 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
US7202223B2 (en) * 2003-10-27 2007-04-10 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2005044835A1 (en) * 2003-10-27 2005-05-19 Genelabs Technologies, Inc. METHODS FOR PREPARING 7-(2'-SUBSTITUTED-ß-D-RIBOFURANOSYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES
WO2006033709A2 (en) * 2004-07-29 2006-03-30 Metabasis Therapeutics, Inc. Novel nucleoside derivatives
TR201815961T4 (tr) * 2008-01-18 2018-11-21 Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Yeni sitostatik 7-deazapürin nükleozidleri.
BRPI0914626A2 (pt) * 2008-06-23 2015-10-20 Janssen Pharmaceutica Nv antagonistas de piperidil acrilamida de ccr2
GB0815968D0 (en) * 2008-09-03 2008-10-08 Angeletti P Ist Richerche Bio Antiviral agents
JP5721275B2 (ja) * 2009-04-22 2015-05-20 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエス シーアール， ブイ．ブイ．アイ． 治療的使用のための新規７−デアザプリンヌクレオシド

Also Published As

Publication number Publication date
JP2015013901A (ja) 2015-01-22
CN104497084A (zh) 2015-04-08
CA2966647A1 (en) 2010-10-28
AU2015205885B2 (en) 2017-04-06
JP2012524731A (ja) 2012-10-18
AU2010238985A1 (en) 2011-12-01
US10294262B2 (en) 2019-05-21
US20170240584A1 (en) 2017-08-24
ES2437917T3 (es) 2014-01-15
US20150218201A1 (en) 2015-08-06
PL2421879T3 (pl) 2014-02-28
WO2010121576A3 (en) 2011-06-16
CN104497084B (zh) 2018-06-05
NZ596301A (en) 2014-10-31
US20160318970A1 (en) 2016-11-03
US9624257B2 (en) 2017-04-18
CA2759131C (en) 2017-06-20
SI2421879T1 (sl) 2014-01-31
AU2017204148B2 (en) 2018-12-06
US9321800B2 (en) 2016-04-26
JP6087889B2 (ja) 2017-03-01
MX2011011160A (es) 2012-01-27
AU2017204148A1 (en) 2017-07-06
CN102459300A (zh) 2012-05-16
CA2759131A1 (en) 2010-10-28
PT2421879E (pt) 2013-12-09
AU2015205885A1 (en) 2015-09-03
DK2421879T3 (da) 2013-11-25
HK1166325A1 (en) 2012-12-14
AU2010238985B2 (en) 2015-04-23
HRP20131021T1 (hr) 2014-01-31
CN102459300B (zh) 2014-12-10
EP2421879A2 (en) 2012-02-29
EP2421879B1 (en) 2013-09-04
WO2010121576A2 (en) 2010-10-28
NZ700583A (en) 2016-04-29
HK1209129A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
JP6087889B2 (ja) 治療的使用のための新規７−デアザプリンヌクレオシド
JP5485172B2 (ja) 新規な細胞増殖抑制性７−デアザプリンヌクレオシド
HK1166325B (en) Novel 7-deazapurine nucleosides for therapeutic uses
HK1234411A1 (en) Novel cytostatic 7-deazapurine nucleosides
HK1209129B (zh) 用於治疗用途的7-脱氮嘌呤核苷
HK1234411B (en) Novel cytostatic 7-deazapurine nucleosides
HK1149016B (en) Novel cytostatic 7-deazapurine nucleosides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140731

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150225

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150323

R150 Certificate of patent or registration of utility model

Ref document number: 5721275

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250